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Abstract
The hydrolysis of GM2-ganglioside is unusual in its requirements for the correct synthesis, processing, and ultimate
combination of three gene products. Whereas two of these proteins are the K- (HEXA gene) and L- (HEXB) subunits of
L-hexosaminidase A, the third is a small glycolipid transport protein, the GM2 activator protein (GM2A), which acts as a
substrate specific co-factor for the enzyme. A deficiency of any one of these proteins leads to storage of the ganglioside,
primarily in the lysosomes of neuronal cells, and one of the three forms of GM2-gangliosidosis, Tay^Sachs disease, Sandhoff
disease or the AB-variant form. Studies of the biochemical impact of naturally occurring mutations associated with the GM2
gangliosidoses on mRNA splicing and stability, and on the intracellular transport and stability of the affected protein have
provided some general insights into these complex cellular mechanisms. However, such studies have revealed little in the way
of structure^function information on the proteins. It appears that the detrimental effect of most mutations is not specifically
on functional elements of the protein, but rather on the proteins’ overall folding and/or intracellular transport. The few
exceptions to this generalization are missense mutations at two codons in HEXA, causing the unique biochemical phenotype
known as the B1-variant, and one codon in both the HEXB and GM2A genes. Biochemical characterization of these
mutations has led to the localization of functional residues and/or domains within each of the encoded proteins. ß 1999
Elsevier Science B.V. All rights reserved.
Keywords: Lysosomal storage disease; Tay^Sachs disease; Sandho¡ disease; AB-variant form; L-Hexosaminidase;
GM2 activator protein
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
1.1. Classical Tay^Sachs disease, i.e. the acute infantile form . . . . . . . . . . . . . . . . . . . . . . 106
1.2. The biochemical link between Hex activity and the GM2 gangliosidoses . . . . . . . . . . . 107
2. The Hex isozymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 9 ) 0 0 0 7 4 - 5
Abbreviations: Hex, human L-hexosaminidase; Activator, the human GM2 activator protein; GM1, GM2, GM3, GA2, see Table 3;
GSL, glycosphingolipid; ER, endoplasmic reticulum; GlcNAc, L-D-N-acetylglucosamine; GalNAc, L-D-N-acetylgalactosamine; MUG, 4-
methylumbelliferyl 2-acetamido-2-deoxy-L-D-glucopyranoside; 4-MUGS, 2-acetamido-2-deoxy-L-D-glucopyranoside-6-sulfate; Sp-Hex,
hexosaminidase from Streptomyces plicatus ; TDS, Tay^Sachs disease; SD, Sandho¡ disease
* Fax: +1-416-813-8700; E-mail : hex@sickkids.on.ca
BBADIS 61879 10-9-99
Biochimica et Biophysica Acta 1455 (1999) 105^138
www.elsevier.com/locate/bba
3. Mechanism of GM2 hydrolysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4. The clinical and biochemical phenotypes of GM2 gangliosidosis . . . . . . . . . . . . . . . . . . . . 120
4.1. Sandho¡ and AB-variant versus Tay^Sachs disease . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.2. Other less-severe GM2 gangliosidosis phenotypes . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.3. The critical threshold hypothesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.4. Mouse models for the GM2 gangliosidoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
5. Intracellular transport of the Hex isozymes and the activator . . . . . . . . . . . . . . . . . . . . . . 122
6. Structure of the HEXA, HEXB and GM2A genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
7. Mutations in the HEXA, HEXB and GM2A genes associated with disease . . . . . . . . . . . . 123
7.1. Partial gene deletions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
7.2. Mutations a¡ecting mRNA splicing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
7.3. Mutations producing premature Stop codons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
7.4. Missense mutations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
8. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
1. Introduction
Lysosomes are acidi¢ed cytoplasmic organelles
which contain an array of degradative enzymes spe-
cialized for the orderly destruction of cellular com-
ponents. The importance of the lysosomal system is
emphasized by the fact that over 35 recessively in-
herited lysosomal storage diseases have been de-
scribed in humans, most of which are the result of
a primary de¢ciency of a single lysosomal enzyme.
These diseases are characterized by the extensive vac-
uolization of cells resulting from the accumulation
of the de¢cient enzyme’s substrate(s). Among the
hydrolytic enzymes in the lysosome are a group of
exo-glycosidases which catalyze the sequential re-
moval of terminal, non-reducing sugar units from
the oligosaccharide component of a variety of large
molecules. This review will deal primarily with the L-
hexosaminidase (L-N-acetylhexosaminidase) iso-
zymes and the GM2 activator protein (Activator).
The former are lysosomal isozymes that cleave the
glycosidic linkages of the non-reducing, terminal L-D-
N-acetylglucosamine (GlcNAc) or L-D-N-acetylgalac-
tosamine (GalNAc) residues on glycolipids, glyco-
proteins, and glycosaminoglycans. The Activator is
a substrate speci¢c (GM2 ganglioside) co-factor for
one of the hexosaminidase isozymes, hexosaminidase
A.
The presence of an N-acetyl-L-D-glucosaminidase
(NAG) was ¢rst reported in 1936 [1]. It was later
found that unlike bacterial NAGs, the mammalian
enzyme has an acidic pH optimum, is found predom-
inantly in lysosomes, and cleaves the terminal non-
reducing, L-1,4-linked, glycosidic bonds of both ami-
no sugars, i.e. GlcNAc and GalNAc. Thus, the ap-
propriate name of the enzyme is L-hexosaminidase or
simply Hex (EC 3.2.1.52). Interestingly, in some seg-
ments of the literature, usually dealing with human
Hex in body £uids, Hex is still incorrectly referred to
as NAG, e.g. [2], which also has an alternative EC
number, EC 3.2.30.
1.1. Classical Tay^Sachs disease, i.e. the acute
infantile form
The early interest in Hex, which has led to its
becoming the primary model for lysosomal glycosi-
dases, was derived from its association with Tay^
Sachs disease. The ‘classical’ infantile form (see be-
low) of Tay^Sachs disease (TSD) has a carrier fre-
quency of about 0.032 in the Ashkenazi Jewish pop-
ulation (0.0039 in the general population) and is one
of the oldest known lysosomal storage diseases. It
was ¢rst described by Dr. Warren Tay, a British
ophthalmologist, in 1881 (Table 1) and results from
the intralysosomal accumulation of GM2 ganglioside
BBADIS 61879 10-9-99
D.J. Mahuran / Biochimica et Biophysica Acta 1455 (1999) 105^138106
(Table 2), primarily in neuronal cells (reviewed in
[3]).
Clinically classical infantile Tay^Sachs patients (or
patients with other infantile forms of GM2 ganglio-
sidosis, see below) show normal development until 3^
6 months of age, at which time motor weakness,
hypotonia, poor head control and decreasing atten-
tiveness begin to cause parental concern. One of the
earliest signs noted by parents is often an exagger-
ated startle reaction to sharp (not necessarily loud)
sounds, characterized by a sudden extension of both
arms and legs. By 10^12 months of age, any motor
skills which had been achieved earlier, such as crawl-
ing and sitting, are lost. Over the next year, vision
diminishes, although distinction between light and
dark may persist, while direct or indirect ophthalmo-
socopy reveals macular pallor with contrasted prom-
inence of the macular fovea centralis (the ‘cherry red
spot’ which initially attracted Dr. Tay’s attention).
Enlargement of the head, also characteristic of this
disorder, is the result of reactive cerebral gliosis,
rather than true hydrocephaly with ventricular en-
largement. By 18 months, neurologic signs of both
upper and lower motor neuron deterioration become
increasingly evident, with seizures becoming a com-
mon occurrence. Further deterioration in the second
year of life invariably leads to the disappearance of
swallowing and gag re£exes, and eventually to a
completely vegetative state. Bronchopneumonia asso-
ciated with aspiration and or diminished capacity to
cough, is frequently antecedent to death. Classical
Tay^Sachs patients usually do not survive beyond
4 years of age [3,4]. This form of Tay^Sachs disease
is found with greatest frequency in the French-Cana-
dian (Table 4, row 1), Cajun (Table 4, row 74), and
Ashkenazi (Table 4, rows 74 and 77) and Moroccan
(Table 4, rows 25, 34 and 56) Jewish populations.
Fortunately, however, the advent of international
carrier detection programs has reduced its incidence
in these groups by 90%.
1.2. The biochemical link between Hex activity and
the GM2 gangliosidoses
Understanding the association between Hex activ-
ity and disease was a complex process for several
reasons. Firstly, whereas the link between Tay^Sachs
disease and a defect in Hex activity was suspected
after the structure of the storage material, GM2 gan-
glioside, was determined (Tables 1^3), total Hex ac-
tivity in samples from Jewish Tay^Sachs patients, as
measured with arti¢cial substrate, was nearly normal.
Table 1
History of the GM2 gangliosidoses
Year Event Reference
1881 Warren Tay: initial description of clinical characteristics, cherry red spot [157]
1896 Bernard Sachs: ‘Amaurotic family idiocy’ prevalent in the Jews [158]
1939 Identi¢cation of a novel class of compounds (gangliosides) stored in amaurotic idiocy [159]
1962 GM2 ganglioside identi¢ed as the compound stored in TSD [160]
1968 Demonstration of two major Hex isozymes in normal human tissue (Hex A and Hex B) [5]
1969 Hex A, but not Hex B is de¢cient in Jewish TSD [6]
1969 Isozyme patterns in non-Jewish TSD patients: (a) de¢ciency of both Hex A and B (SD); (b) no Hex
de¢ciency (AB-variant or B1-variant)
[7]
1973 Immunological basis for the subunit compositions of Hex A (KL) and B (LL) : de¢ciency of the K results
in TSD, de¢ciency of L results in SD
[161]
1979 Puri¢cation and characterization of the GM2 Activator protein: its de¢ciency results in the AB-variant
form
[162]
1984-1985 Isolation of cDNA clones encoding the K- and L-subunits [69,163]
1986 Identi¢cation of partial HEXA and HEXB gene deletions resulting in infantile TSD and SD (Table 4,
row 1; Table 5, row 3)
[18,76]
1988 Identi¢cation of two major HEXA mutations responsible for TSD in Ashkenazi Jews (Table 4,
rows 74 and 77)
[164^166]
1989^1992 Isolation of a cDNA clone encoding the GM2 activator [74,75,167]
1991^1992 Association of a GM2A mutation with the AB-variant form (Table 6, row 3) [154,155]
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It was not until 1968 when Robinson and Stirling
separated the total Hex activity from human spleen
into two pI forms (an acidic, Hex A, and a basic,
Hex B, form) [5], and Okada and O’Brien found that
Hex A was missing in their Jewish patients that it
was recognized that total Hex activity was derived
from at least two gene products [6], i.e. Hex A and
Hex B were true Hex isozymes (see below and Table
1). In Jewish Tay^Sachs patient samples Hex B levels
increase su⁄ciently to mask the lack of Hex A.
Secondly, in contrast to the straightforward Hex
A-de¢ciency found in Jewish patients, Sandho¡ ana-
lyzed samples from both Jewish and non-Jewish
‘Tay^Sachs’ patients and found that some of the lat-
ter were missing both Hex A and Hex B or even
more confusingly, appeared to have normal levels
of both isozyme [7,8]. These results were not under-
stood until the structure of the Hex isozymes, their
substrate speci¢cities, and the role of the Activator
protein had been determined.
Thirdly, solid structural data on the isozymes were
di⁄cult to obtain. We now know that, whereas Hex
B is a homodimer of L-subunits, Hex A is a hetero-
dimer consisting of an K- and a L-subunit. Two evo-
lutionarily related genes encoded these subunits, K by
the HEXA gene (15q23^q24, [9]) and L by the HEXB
gene (5q13 [10]). Thus, Jewish Tay^Sachs disease re-
sults from HEXA mutations which only a¡ect Hex A
formation, and patients lacking both isozymes have
another form of GM2 gangliosidosis, Sandho¡ dis-
ease, caused by HEXB mutations which a¡ects the
common L-subunit (Table 5). Confusion over the
structures of each isozyme, including the number of
subunits in each and their relationship to each other,
as well as the number of polypeptides contained
within the subunits existed for sometime. The confu-
sion arose because in vivo Hex is a rare protein re-
quiring 6000^10 000 fold puri¢cation from human
tissues, and its intra- and extra-cellular isozymes
are heterogeneous with respect to both their sub-
units’ polypeptide chain structures and carbohydrate
contents. Thus each isozyme has multiple pI and
apparent molecular weight (Mr) forms (particularly
when viewed by SDS-PAGE) [11^13]. This hetero-
geneity results from the initial gene products, the
prepro-K- and L-polypeptides, undergoing extensive
post-translational modi¢cations starting in the endo-
plasmic reticulum (ER) (where they are synthesized)
and Golgi, followed by ¢nal proteolytic and glycosi-
dic processing in the lysosome to produce the mature
Table 3
GLS structures
Glycolipid Oligosaccharide structure
GalNAc-GD1a GalNAcL(1^4)-Gal-[K(2^3)NeuAc-]L(1^3)GalNAcL(1^4)Gal [K(2^3)-NeuAc]L(1^4)Glc-Ra
GD1a Gal-[K(2^3)NeuAc-]L(1^3)GalNAcL(1^4)Gal [K(2^3)-NeuAc]L(1^4)Glc-R
GM1 GalL(1^3)GalNAcL(1^4)Gal-[K(2^3)NeuAc-]L(1^4)Glc-R
GD2 Gal[K(2^3)NeuAc-K(2^8)NeuAc-]L(1^4)Glc-R
GM2 GalNAcL(1^4)-Gal[K(2^3)NeuAc-]L(1^4)Glc-R
GM3 Gal[K(2^3)NeuAc-]L(1^4)Glc-R
GA2 GalNAcL(1^4)GalL(1^4)Glc-R
Gb4 GalNAcL(1^4)GalK(1^4)GalL(1^4)Glc-R
aR = ceramide.
Table 2
Storage of GSL in the GM2 gangliosidoses
GM2a GD2a GD1aa GalNAc-GD1aa* GA2a Gb4b
Control 20 40 500 2 0 180
Tay^Sachs 10 000 80 400 30 1 000 400
Sandho¡ 9 000 100 300 10 5 000 2 000
AB-variant 18 000 90 200 2 4 000 200
aTotal brain GSL, nmol of ganglioside per g wet weight of tissue ([4] or *[30]).
bTotal kidney globoside, nmol of globoside per g wet weight of tissue [4].
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Table 4
HEXA gene mutations associated with Tay^Sachs disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
1. v7.6 kb 5P to 1-IVS No mRNA Abnormal Southern blot,
no mRNA
Acute 82% of French-Canadian
TSD
[77,78,168]
2. A1CT 1-exon Met1CLeu Protein initiation site Chronic (second
allele = Gly269Ser
[169]
3. A1CG 1-exon Met1CVal Protein initiation site Acute American Black [170]
4. T2CC 1-exon Met1CThr Protein initiation site Severe subacute (second
allele = Pro25CSer)
Non-Jewish (UK) [171]
5. C73CT 1-exon Pro25CSer Hex A 6 2.5%a, similar to
Gly269CSer mutation, soluble
precursor no detectable mature
form, transport mutant
Severe subacute (second
allele = Met1CThr)
Non-Jewish (UK) [171]
6. G78CA 1-exon Trp26CStop Acute UK, Israeli, Arab [70,172]
7. T116CG 1-exon Leu39CArg Low level of pro-K no mature Acute (second allele =
exon 11 insertion)
Non-Jewish [173]
8. C316CT 2-exon Gln106CStop Acute Various [174]
9. gCc 2-IVS+1 Abnormal splicing Acute European [70]
10. gCa 2-IVS+1 Abnormal splicing Low level of mRNA lacking
exon 2
Acute French [175]
11. C379CT 3-exon Leu127CPhe Acute Various [174]
12. T380CG 3-exon Leu127CArg 50% mRNA Acute (second = ?) Italian [173]
13. C409CT 3-exon Arg137CStop mRNA undetectable (second
allele+TATC1278^1281)
Acute French, Irish [170,175]
14. gCt 3-IVS+1 Abnormal splicing Skips exon 3 Acute Japanese [176]
15. vTT423^4 4-exon v142 No mRNA by Northern blot Acute (homozygous) French [173]
16. vG436 4-exon Frame shift (exon
6^Stop)
Acute (homozygous) US, Black [170]
17. +t 4-IVS+3t skips exon 4 early
Stop, 17 bp
downstream
No normal mRNA severely
reduced misspliced mRNA
Acute (homozygous) Israeli-Bedouin [177]
18. gCa 4-IVS+5 Abnormal splicing 3% mRNA lacking exon 4 Acute (second allele =
+TATC1278^1281)
French [175]
19. gCt 4-IVS31 Abnormal splicing Acute (homozygous) US, Black [178]
20. vTG477^8 5-exon Frame shift Stop = +2 codons Acute UK [70]
21. C496CG 5-exon Arg166CGly Second allele =vC498 Syrian [179]
22. vC496 5-exon Frame shift 5% mRNA Subacute (second
allele = Ser297Pro)
Israeli Druze [180]
23. vC498 5-exon Frame shift, Stop
96 bp downstream
Stop = +32 codons Second allele = Arg166Gly Syrian [179]
24. C508CT 5-exon Arg170CTrp Acute (second = Gly454Ser) Italian, French-Canadian [70,148,173]
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Table 4 (continued)
HEXA gene mutations associated with Tay^Sachs disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
25. G509CA 5-exon Arg170CGln
(CpG)+abnormal
splicing
mRNA splicing cryptic site 351 bp
at 5P-end of exon. Patient cells ;
protein of reduced size. COS
expression of missense as Hex S
(K*K*) formed in reduced amounts
and is unstable
Acute 37% of TSD in Moroccan
Jews; Japanese, Scottish
[173,181,182]
26. C532CT 5-exon Arg178CCys (CpG) B1-like catalytic defect; Hex S
expression = inactive (likely some
additional transport problems)
Acute Czech [141]
27. G533CA 5-exon Arg178CHis (CpG) B1-classic : normal mRNA and Hex
A (K*L) levels with MUG, but
inactive with MUGS. COS
expression = no Hex S (K*K*)
activity; Hex B (Arg211CHis or Lys)
analogs normal levels of mature
L*L*-CRM no activity with MUG
Subacute in homozygotes
(severe subacute in
compound with null
allele)
Common in Portuguese,
Diverse
[61,138^
141,145]
28. G533CT 5-exon Arg178CLeu B1-like, 19% serum Hex A (MUG)
(likely some additional transport
problems)
Acute (second
allele = Trp26CStop)
UK [70]
29. T538CC 5-exon Tyr180CHis Protein unstable at physiological
temperatures
Chronic Ashkenazi Jewish [117]
30. C540CG 5-exon Tyr180CStop Decreased mRNA Acute 2% of TSD in Moroccan
Jews
[182]
31. 547insA 5-exon Frameshift Stop = +2 codons, no detectable K-
CRM
Acute (homozygous) Chinese [183]
32. G570CA 5-exon31 Silent mutation in
last bp (Leu) of
exon, CTG a¡ects
splicing
7% of mRNA lacking exon 5, 3%
normal mRNA, 2.5% Hex Aa
Severe subacute
(homozygous)
Tunisian [86,184]
33. gCa 5-IVS+1 Abnormal splicing Acute Turkish [184]
34. aCg 5-IVS32 Abnormal splicing 12% of TSD in Moroccan
Jews
[185]
35. gCt 5-IVS31 Abnormal splicing Inframe deletion of exon 6, normal
levels of shortened mRNA, protein
is trapped in the ER, transport
mutation
Acute (homozygous 80% of TSD in Japanese [96]*
36. (a) G574CC,
(b) G598CA
6-exon (a) Val192Leu is
detrimental ;(b)
Val200Met (neutral)
Previously reported as a B1. Re-
examined in transfected CHO cells
and patient ¢broblasts, only pro-K
detected by Western blot, i.e.
transport mutation
Acute second allele
9-IVS+1
European [136,186^
188]
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Table 4 (continued)
HEXA gene mutations associated with Tay^Sachs disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
37. A590CC 6-exon Lys197CThr Normal mRNA Chronic (second
allele = Arg499His)
Dutch [173]
38. A611CG 6-exon His204CArg Acute (second allele =
exon 11 insertion)
German [173]
39. C629CT 6-exon Ser210CPhe Suggested catalytic defect
(unlikely), Normal mRNA
Acute Algerian N. African [175,189]
40. T632CC 6-exon Phe211CSer Normal mRNA Acute (second
allele = Arg499Cys)
Italian [173]
41. C677CT 6-exon Ser226CPhe Azore [174]
42. gCa 6-IVS+1 Abnormal splicing Skips exon 6, 50% mRNA Subacute (second?) US [173]
43. C739CT 7-exon Arg247CTrp Reduced activity and K-CRM,
Hex A is formed but unstable
Asymptomatic in
compounds with null
allele
Diverse, V5% of enzyme-
based carriers in non-Jews,
6 3% in Jews
[118,126,
190^193]
44. C745CT 7-exon Arg249CTrp Reduced activity and K-CRM,
Hex A is formed but unstable
Asymptomatic in
compounds with null
allele
French Canadian
[70,118,127,191]
45. G748CA 7-exon Gly250CSer Reduced activity, but not found in
any patients with TSD
pseudo-de¢ciency? French Canadian [193]
46. G749CA 7-exon Gly250CAsp (CpG) Hex A = 2^3%a ; COS expression,
no Hex S activity, Hex A activity
and CRM intermediate (12%),
transport mutation
Subacute Lebanese [194,195]
47. G755CA 7-exon Arg252CHis Chronic Portuguese [196]
48. G772CC 7-exon Asp258CHis B1-like, patient sample = 16%
Hex A with MUG, 6 1% with
MUGS; CHO expression of Hex B
analog, Km = 3U higher plus
transport problems
Severe subacute [148^150]
49. gCc 7-IVS+1 Abnormal splicing mRNA undetectable Acute (homozygote) Portuguese [197]
50. gCa 7-IVS+1 Abnormal splicing mRNA undetectable Acute (second allele =
v7.6 kb)
French-Canadian [70,198]
51. gCa 7-IVS37 Abnormal splicing New 3P-splice acceptor 5 bp
upstream, lacking exon 8 mRNA =
6%, normal mRNA = 10%
Chronic (second
allele = exon 11 4 bp
insertion)
Canadian/ English [199]
52. G805CA 7-exon31 Gly269CSer plus
abnormal splicing
Hex A = 4^6%a ; 50% mRNA due
to splicing defect. COS expression,
Hex S (K*K*) inactive, Hex A
(K*L) = 40%, however it is unstable
at 37‡C
Chronic with null allele,
homozygotes at mild end
of spectrum
Ashkenazi 3%, 5% in
non-Jews with TSD
[87,88,143]
[102,170,
200,201]
53. G806CA 8-exon Gly269CAsp [174]
54. T835CC 8-exon Ser279CPro Severe subacute, second
allele vC496
Israeli-Druze [180]
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Table 4 (continued)
HEXA gene mutations associated with Tay^Sachs disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
55. T902CG 8-exon Met301CArg Normal mRNA Acute
(second = Arg504CHis)
Yugoslavian [173]
56. vTTC910^912 8-exon vPhe304 or 305 Transport mutation; COS
expression Hex S inactive, pro-K
CRM only
Acute 43% of TSD in Moroccan-
Jew(Irish, French)
[170,175,182,202]
57. vCT927^28 8-exon Frame shift Stop = +12 codons, no mRNA Severe subacute (with B1) German Scandinavian [148]
58. A941CT 8-exon Asp314CVal Ashkenazi Jews,
Irish-English
[174]
59. vGGA958^961 8-exon vGly320 or 321 Severe subacute Irish [170]
60. aCg 8-IVS+3 Abnormal splicing Loss of exon 8 Severe subacute (second
allele = Arg178His (B1))
[203]
61. G987CA 9-exon Trp329CStop Acute (if second allele =
B1, severe subacute)
English, German [170]
62. A1003CT 9-exon Ile335CPhe A¡ected prenatal Non-Jewish [204]
63. 1039del18 9-exon del 6 aa? A¡ected prenatal Ashkenazi Jewish [204]
64. gCa 9-IVS+1 Abnormal splicing Low levels of mRNA with several
cryptic splices; no normal mRNA
Acute Major non-Jewish mutation;
8% of Cajun, 17% of W.
Europeans
[205^209]
65. 1074-vtctcc 9-IVS38^12 Abnormal splicing Low mRNA, most missing exon 10 Acute (second
allele+TATC1278)
Polish [70]
66. gCt 9-IVS31 Abnormal splicing Acute Irish, French [210]
67. C1168CT 11-exon Gln390CStop [174]
68. G1171CA 11-exon Val391CMet Chronic (second allele =
Arg178His (B1))
Greek [211]
69. G1176CA 11-exon Trp392CStop Acute Ashkenazi [212]
70. C1177CT 11-exon Arg393CStop No mRNA Acute (homozygous) French, Turkish [175,184]
71. vG1182 or
1183
11-exon Frame shift Stop = +3 codons Acute (obligate carrier) US [204]
72. 1204 del 3 11-exon Lys402del [174]
73. G1260CC 11-exon Trp420CCys COS expression, no Hex S
activity; likely transport mutation
Acute German [213]
74. +TATC1278 11-exon Frameshift Stop = +4 codons; absent mRNA
in patients’ cells, normal trans-
cription rate; COS
expression = signi¢cant levels of
mRNA producing truncated,
pro-K-CRM
Acute 20% of Non-Jews, 75% of
Ashkenazi Jews, 92% of
Cajuns; 2% of Moroccan
Jews
[97,164,
170,185,205]
75. G1360CA 12-exon Gly454CSer Normal mRNA Acute (second allele =
Arg170Trp)
Italian [173]
76. G1373CA 12-exon Cys458CTry COS expression = no Hex S activity Acute Japanese [176]
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Table 4 (continued)
HEXA gene mutations associated with Tay^Sachs disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
77. cCg 12-IVS+1 Abnormal splicing No normal mRNA, trace of
abnormal mRNA retaining intron
12 or excluding exon 12
Acute 15% of TSD in Ashkenazi,
2% in Morrocan Jews
[165,166,185,214]
78. G1422CC 13-exon Trp474CCys (1st
nucleotide in exon)
Possibly some abnormal splicing.
In patient sample 5%a Hex A;
COS expression (K*L) 12% Hex
S+A, transport mutation
Subacute (second allele =
4 bp insertion)
Non-Jewish [215]
79. G1444CA 13-exon Glu482CLys (CpG) Patient sample, Hex A = 6 1%a ;
protein cannot exit ER, i.e.
transport mutation
Acute 2% of TSD in Moroccan
Jews;Chinese, Italian
[183,185,216,217]
80. T1451CC 13-exon Leu484CPro COS expression, no Hex S activity,
likely transport mutation
Acute Japanese [176]
81. T1453CC 13-exon Trp485CArg COS expression, no Hex S activity,
likely transport mutation
Acute Chinese [183]
82. C1495CT 13-exon Arg499CCys Acute (if second allele
Gly269Ser (chronic))
Slavic, Irish, English,
Polish
[170,218]
83. G1496CA 13-exon Arg499CHis (CpG) Patient cells ; decreased solubility of
pro-K, most cannot exit ER, 3%
Hex Aa, transport mutation
Subacute Scottish-Irish, Jewish [70,218,219]
84. vC1510 13-exon Frame shift, Stop+4
aa, loss of 22 aa
Normal levels of mRNA, truncated
K that cannot exit ER and is
degraded, transport mutation
Acute (homozygous) Italian [98,220]
85. C1510CT 13-exon Arg504CCys (CpG) Inhibited subunit asso? COS
expression, no Hex S dimers or
activity; transport mutation
Acute (homozygous) Diverse
[173,175,176,221]
86. G1511CA 13-exon Arg504CHis (CpG) Patient cells ; K does not associate
with L, but is phos. and can be
secreted with NH4Cl. COS expression
Hex S fails to form, transport
mutation
Subacute (homozygous) Diverse [176,219,222]
87. 1549 ins C 14-exon frameshift Acute Ecuadorean [174]
aResidual Hex A activity in patient cells (% normal) if known.
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Table 5
HEXB gene mutations associated with Sandho¡ disease
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
1. 50 kb deletion 25 kb 5P-pro-
moter^intron 6
No mRNA No mRNA or L-protein Acute (second
allele = Ser62Leu)
[83]
2. (50 kb) dele-
tion: re-tested
same as 16 kb be-
low
1^5-
exons+promoter
No mRNA No mRNA or L-protein, Same
mutation as [18,79]
Acute Diverse 11/28, 30% of
SD alleles
[80,82]
3. 16 kb deletion 1^5-
exons+promoter
No mRNA No mRNA or L protein Acute Diverse 8/30, 27% of
SD alleles
[79]
4. vA76 1-exon Frame shift Acute Cyprus Maronite [223]
5. C185CT 1-exon Ser62CLeu Acute (second allele =v50
kb)
[83]
6. gCa 2-IVS+1 Abnormal splicing Unstable mixture of abnormal
mRNA, linked to Pst polymorph
Acute Argentinean (common
mutation)
[224^226]
7. A619CG 5-exon Ile207CVal Originally suggested impaired
activator binding, but has now
been shown to be a neutral
polymorphism
Chronic, motor neuron
disease (second
allele = Tyr456CSer)
Not reported [83,227^229]
8. vCTTT782ÿ5 7-exon frameshift at Tyr260 Early Stop codon at 273, unstable
mRNA
Acute Argentinean [224,226]
9. vG772 7-exon Frameshift at Gly258 Early Stop at codon 274, unstable
mRNA
Acute (second allele =vAG)Not reported [99,230]
10. C850CT 7-exon Arg284CStop 0.8% mRNA Acute [99]
11. G890CA 8-exon Cys297CTyr Chronic (second
allele = Pro417Leu)
Italian [92]
12. C1252CT 11-exon+8 Abnormal splicing,
Pro417CLeu is neutral
Unstable mRNA (P2 and P3)
P1 = normal mRNA; 8% of
normal mRNA levels of which
80% is P1, aa substitution is silent
(a) Subacute (homozygous);
(b) very mild (second
allele =v16 kb)
(a) Japanese;
(b) French-Canadian;
(c) Italian
(a) [71](b)
[90](c) [92]
13. vAG1305ÿ6 11-exon Frameshift, at Arg/
Val436
Early Stop at codon 454, 1.8%
mRNA
Acute (second allele =vG) Not reported [99,230]
14. vT1344 11-exon Frameshift Early Stop at codon 451, 30%
mRNA
Acute (second allele =v16
kb
[99]
15. A1367CC 11-exon Tyr456CSer No L-protein, transport mutant
(second disease allele reported to
be Ile207CVal, but this substitution
was found to be neutral)
Chronic, motor neuron
disease (probably due to
second unknown allele)
Not reported [227^229]
16. gCa 12-IVS*326 Abnormal splicing
(‘a’ moves to 32
position)
Insertion of 8 aa, normal mRNA
levels, s 97% Abnormal splicing,
unstable elongated L-chain,
3% Hex Aa undetectable^Hex B
Subacute (second
allele =v16 kb)
Caucasian, Japanese [89,91,231]
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forms (Figs. 1 and 2) (reviewed in [3,14,15]). The Hex
in extracellular £uids originates from two sources. (a)
The intracellular transport of Hex does not result in
100% of the protein being incorporated in the lyso-
some. Some of the Hex isozymes in their precursor
forms escape this pathway and are secreted (Fig. 2).
(b) Cell death releases mature forms of the Hex iso-
zymes.
Fourthly, it was found that Hex A alone is not
su⁄cient to hydrolyze GM2 ganglioside, in vivo,
where the reaction requires a third gene product,
the GM2 activator protein (Activator) encoded by
the GM2A gene 5q 31.3^33.1 [16], as a ‘substrate
speci¢c co-factor’ (Fig. 3). This explains Sandho¡’s
most confusing observation of a patient with appar-
ently normal levels of both Hex isozymes.
In summary, mutations in any of three genes can
lead to a blockage in GM2 degradation. Since gan-
gliosides are synthesized primarily in neuronal cells,
these are the cells most a¡ected by the disease (Ta-
bles 2 and 3). When the storage of GM2 reaches
some critical value these cells are destroyed, possibly
through apoptosis [17], resulting in one of three dis-
eases with similar clinical phenotypes, the GM2 gan-
gliosidoses: (1) Tay^Sachs, K-defects (Table 4); (2)
Sandho¡, L defects (Table 5); and (3) the AB-var-
iant, Activator defects (Table 6).
For all the above reasons the literature dealing
with Hex published in the 1970s and early 1980s
contained numerous contradictory and/or incomplete
models for the structures and relationships of the
Hex isozymes (reviewed in [14,15]). The present era
of solid structural data on the Hex isozymes (re-
viewed in [3]) has been ushered in by the isolation
of cDNA clones encoding the two Hex subunits, as
well as those encoding the Activator protein (Table
1).
2. The Hex isozymes
There are two major Hex isozymes in normal hu-
man tissue. Hex A (pI = 4.8) is a heterodimer, KL,
whereas Hex B (pI = 6.9) is a homodimer, LL. A
third, unstable isozyme, Hex S (pI = 3.4), is com-
posed of two K-subunits. Hex S accounts for the 1^
6% of normal activity found in human cells that do
not synthesize functional pro-L-polypeptides, i.e.Ta
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Sandho¡ cells [18,19]. The heat stability as well as
the pI values of the isozymes di¡er [5,20], Hex
BsHex AEHex S. Thus isozyme separation can
be achieved by techniques like ion^exchange chroma-
tography or isoelectric focussing, and for diagnostic
purposes the %Hex B of the total present can be
calculated after speci¢cally heat-denaturing Hex A
[21,22]. The number of exons and the location of
exon^intron junctions in the HEXA and HEXB
genes are very similar [23], and their aligned cDNA
sequences encode proteins that are 60% identical [24].
Thus these genes arose from a common ancestral
Fig. 1. The aligned primary structures of the K- and L-subunits of human Hex A. The N-terminal signal peptide of each prepro-poly-
peptide is underlined. Sites (N-X-S/T) shown to contain N (Asn)-linked oligosaccharides are also underlined with the ‘Ns’ linked to
those carbohydrates receiving a mannose-6-phosphate, lysosomal targeting moiety, double underlined. Sequences comprising to the
mature, lysosomal Kp and Lp chains are in ‘[]’, those making up the Km and Lb chains are in ‘{}’, and those associated with the La
chain are in ‘()’. The residues between di¡erent bracket sets are presumably lost during lysosomal processing. Residues in bold, larger
sized fonts are predicted to be in the active site of the subunits based on molecular modeling from the crystal structure of bacterial
chitobiase [131], mutations in those underlined are associated with the B1-variant of Tay^Sachs disease.
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gene and it would be expected that the K- and L-
subunits have the same overall three-dimensional
structure. This hypothesis is consistent with the abil-
ity to form dimers with similar substrate speci¢cities
from any combination of the two subunits (see be-
low) [25].
Although only dimeric forms of Hex are active, the
existence of the three Hex isozymes (LL, KL, and KK)
indicates that each subunit contains all the elements
necessary to form one active site. The active sites
associated with both the K- and L-subunits hydrolyze
many of the same neutral arti¢cial substrates (com-
mon substrates), e.g. MUG (4-methylumbelliferyl 2-
acetamido-2-deoxy-L-D-glucopyranoside) [25], and
several natural ones (reviewed in [15]). However,
only the presence of the active site associated with
the K-subunit results in the e⁄cient hydrolysis of
negatively charged substrates, e.g. L-linked N-acetyl-
glucosamine 6-sulfate containing glycosaminoglycans
[25^27] and arti¢cial substrates [25,27], e.g. 4-MUGS
(2-acetamido-2-deoxy-L-D-glucopyranoside-6-sulfate)
[28], and, most importantly, GM2 ganglioside (Fig.
3). In the latter case the L-subunit also plays a role,
presumably in substrate (Activator:GM2 ganglioside
complex) binding [29], as only the K-subunit in its
heterodimeric Hex A isozyme is functional in vivo
[30]. The Km and Vmax of Hex A and B for MUG
are nearly identical (Km = 0.7^0.9 mM and
Vmax = 10^20 mmol h31 mg31) [25,31]. The Km for
MUGS is 0.2^0.3 mM for Hex A and about ten-
times this concentration for Hex B (it is di⁄cult to
calculate for Hex B because of the limited solubility
of the substrate). This does not mean that Hex B
cannot hydrolyze MUGS only that its rate of hydrol-
ysis at normal assay concentrations is about 1.3%
that of Hex A, i.e. MUG:MUGS = 4:1 for Hex A
and 300:1 for Hex B [25].
3. Mechanism of GM2 hydrolysis
GM2 is an intermediate in both the synthesis (ER)
and degradation (lysosome) of the higher brain gan-
gliosides, e.g. GM1 (Table 3). In order to hydrolyze
GM2, Hex A requires the small, monomeric, heat
stable GM2 activator protein (Activator, Fig. 3).
The Activator interacts with both the carbohydrate
and lipid portion of the ganglioside, and it eliminates
steric hindrance from the membrane by solubilizing a
ganglioside molecule [30]. As well, Activator binding
may interrupt a speci¢c hydrogen bond between the
acetamido-NH of the GalNAc residue and the car-
boxylic group of the NeuAc residue of GM2, making
the GalNAc available for hydrolysis by Hex A [32].
The relative importance of these two functions is
currently a matter of debate in the literature (re-
viewed in [33]). The Activator:GM2 complex then
speci¢cally interacts with Hex A with a Km of
V0.2 WM [34]. However, its rate of MUGS:GM2
hydrolysis is V800:1 [25]. Surprisingly, this indicates
Fig. 2. Flow chart depicting the biosynthesis, intracellular transport and assembly of the Hex isozymes. [ProK/L]UF indicates the con-
centration of unfolded K- or L-pro-polypeptides, whereas [ProK/L]F indicates the concentration of either folded subunit. Transport
from the cis Golgi to the TGN is through bulk-£ow with secretion being the cell’s default pathway.
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that Hex A’s second order rate constants, i.e. its
catalytic e⁄ciency, are similar for arti¢cial and nat-
ural substrates, i.e. kcat/Km (800/0.25U1033 M
(MUGS) V1/0.2U1036 M (Activator:GM2)). In
vivo substrate speci¢cities and the need for the pres-
ence of the Activator can also be inferred from the
compounds that are stored in the various GM2 gan-
gliosidoses (Table 2).
In vitro assays can utilize detergents as a substitute
for the Activator. Under these conditions Hex S, as
well as Hex A, but not Hex B, can e⁄ciently hydro-
lyze GM2. Interestingly, Hex B can hydrolyze GA2,
the neutral, asialo derivative of GM2 in the presence
of detergent, but has little or no activity in the pres-
ence of activator alone. As well the Activator, even
in the absence of GM2, has been reported to inhibit
the hydrolysis of MUGS by both Hex A and Hex S
(reviewed in [4,35]). These data indicate that the
binding site for the complex, as well as the negatively
charged substrate, is located in the K-subunit, but
Fig. 3. Cartoon outlining the steps in the degradation of GM2 ganglioside by Hex A and the Activator (adapted from [4]).
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Table 6
GM2A gene mutations associated with the AB-variant form of GM2 gangliosidosis
Mutation Location Result Biochemical phenotype Clinical phenotype Heritage Ref.
1. vAAG262^264 3-exon vLys88 Normal mRNA, no mature CRM,
transport mutation; 8.4 þ 0.4%
residual activity after bacterial
expression
Acute (homozygous) Saudi Arabian consanguinity [237]
2. vA410 3-exon 33 new aa, loss of 24 Normal mRNA, no mature CRM,
transport mutation; 3% þ 0.2 residual
activity after bacterial expression
Acute (homozygous) Spanish consanguinity [237]
3. T412CC 3-exon Cys138CArg No detectable CRM in patient cells,
COS expression low ProAct CRM no
function, transport mutation;
bacterial expression demonstrated the
protein retained ganglioside transport
function, but reduced interaction with
Hex A
Acute (homozygous) US Black [34,154,155]
4. G506CC 4-exon Arg169CPro Premature degradation of the mutant
GM2 activator, transport mutation
Acute [238]
5. G160CT 2-exon Glu54CStop No detectable mRNA or CRM Acute (homozygous) Laotian, Hmong [239]
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that elements of the L-subunit (other than its active
site [25]) are necessary to somehow correctly align
the complex and allow hydrolysis of the ganglioside.
Further functions that have been identi¢ed for the L-
subunit are to greatly increase the stability of the
resulting dimer and to facilitate the transport of the
K-subunit out of the ER (see below) (reviewed in
[3,33,36]).
4. The clinical and biochemical phenotypes of
GM2 gangliosidosis
4.1. Sandho¡ and AB-variant versus Tay^Sachs
disease
Unlike Tay^Sachs disease, no predominant ethnic
group has been shown with a high Sandho¡ disease
(Table 5) or AB-variant (Table 6) disease incidence.
To date only 8 patients with the AB-variant form
have been reported [3,37] and ¢ve mutations charac-
terized (Table 6). However, a number of geographic
isolates, or demes, have been identi¢ed with a high
incidence of Sandho¡ disease. For example, 36 cases
of acute Sandho¡ disease, belonging to 27 families,
most of which traced their ancestry to a geographi-
cally isolated area encompassing the northwestern
region of the province of Cordoba in Argentina,
were diagnosed over a 7-year period [38] (Table 5,
row 6). In addition to the total de¢ciency of both
Hex A and B activity in Sandho¡ disease (compared
with just a loss of Hex A activity in Tay^Sachs dis-
ease), other distinguishing clinical features of Sand-
ho¡ disease include the presence of organomegaly
and occasional bony deformities, similar to those as-
sociated with infantile GM1 gangliosidosis. Clinical
laboratory ¢ndings that may also distinguish the two
disorders include occasional foamy histiocytes in the
bone marrow as well as the presence of N-acetylglu-
cosamine-containing oligosaccharides in the urine of
patients with Sandho¡ disease. Because of the few
reports on AB-variant patients (Table 6), little can
be generalized about their clinical phenotype. Most
present with a disease similar to (including the cherry
red spot), but perhaps slightly milder than the acute
form of Tay^Sachs disease [37]. Biochemically, they
have normal levels of Hex A and Hex B measured
with both the MUG and MUGS arti¢cial substrates.
4.2. Other less-severe GM2 gangliosidosis phenotypes
Although the most severe infantile forms of GM2
gangliosidosis have a rather homogeneous clinical
presentation (see above), there are less severe forms
which show extreme variability in expression. Typi-
cally, the earlier the age of onset of clinical symp-
toms the more severe the disease. Thus, in the past,
patients have been classi¢ed strictly according to
their age at onset. However, because this system is
so variable, i.e. dependent on the initial timing of the
diagnosis, a more general nomenclature based on the
di¡erent clinical phenotypes and recognizing the
dominance of the encephalopathy has been suggested
[3] : acute (the classical infantile form, see above);
subacute (late infantile and juvenile forms); and
chronic (adult and chronic forms).
Patients with subacute GM2 gangliosidosis present
the same symptoms as acute patients; however, onset
is delayed, with motor ataxia ¢rst becoming evident
at 2^6 years of age, and death occurring by age 10^
15 years. Chronic patients usually present with ab-
normalities of gait and posture between 2 and 5 years
of age. Most of the patients with this condition are
still living in their third to fourth decade of life. This
is the most clinically variable type of GM2 ganglio-
sidosis with extreme variability of symptoms and
course which can even be found in the same family
or sibship. Clinically, symptoms of spinocerebellar
and lower motor neuron dysfunction are most prom-
inent. Psychosis, usually of the schizophrenia type
with slow personality disintegration, often with epi-
sodes of depression, is evident or develops in one-
third of patients. Because of the diversity in clinical
symptoms associated with the adult phenotype, pa-
tients have been previously misdiagnosed with an
array of disorders, including spinal muscular atro-
phy, atypical Friedreich ataxia and Kugelberg^We-
lander disease [39^42].
4.3. The critical threshold hypothesis
Whereas mutations that cause the complete loss of
Hex A activity, e.g. partial HEXA or HEXB gene
deletions (see below), give rise to the acute form of
GM2 gangliosidosis which is a devastating disease
(see above), it is believed that mutations leaving
even very small levels of residual Hex A activity
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give rise to diseases of later onset and milder course.
Utilizing an assay system employing the GM2 acti-
vator protein and radiolabeled GM2 ganglioside as a
substrate, a correlation between residual Hex A ac-
tivity and the severity of the resulting disease has
been determined [43]. Activities found for acute, sub-
acute, and chronic patients were 90.1, 0.5, and 2^4%
of normal controls, respectively. Two clinically
healthy probands with low Hex A activity were
found to possess activities of 11 and 20% [44].
Thus, these data suggest a ‘critical threshold’, i.e.
the minimum amount of Hex A activity required to
keep the rate of GM2 hydrolyzed greater than or
equal to the rate of ganglioside transport and incor-
poration into the lysosome, for Tay^Sachs and
Sandho¡ disease of between 5 and 10% of normal
Hex A activity [45].
4.4. Mouse models for the GM2 gangliosidoses
Mouse models have been made for Tay^Sachs dis-
ease, Sandho¡ disease and the AB-variant. As in
human, total Hex levels are v50% in the Tay^Sachs
mouse (from Hex B), while levels in the Sandho¡
mouse are 6 1.5% (from Hex S). Interestingly,
whereas the Sandho¡ mouse presents with a clinical
phenotype similar to that observed in human pa-
tients, the Tay^Sachs mouse does not develop a clin-
ical phenotype, despite having biochemical and his-
tological evidence of GM2 storage. The storage
material in this mouse also di¡ered from human pa-
tients and suggested the reason for the lack of a
phenotype. In the Tay^Sachs mouse, there was no
elevation in GA2 (the asialo-derivative of GM2, Ta-
ble 3) levels. In humans with Tay^Sachs disease the
GA2 levels are V10% of the GM2 levels, with
Sandho¡ disease or the AB-variant form levels are
50% of GM2, Table 2 [4]. In the Sandho¡ mouse,
levels of GM2 were increased only V3-fold. In hu-
mans with any of the three forms, 500-fold increases
are seen (Table 2) [4]. However, in the Sandho¡
mouse, there was a dramatic increase in GA2. Based
on this observation and radioactive GM1 (Table 3)
feeding experiments with mutant mouse cells, it was
concluded that in mice, unlike humans, the conver-
sion of GM2 to GA2 by a lysosomal sialidase is a
functional alternative pathway. Because either Hex A
or Hex B can hydrolyze GA2; although in vivo Hex
B hydrolysis is very slow [46,47], the normal levels of
Hex B in the Tay^Sachs mouse are su⁄cient to dra-
matically slow down the storage of GM2 and GA2.
The Sandho¡ mouse is fertile during the early part
of its life, and was bred with the Tay^Sachs mouse to
produce o¡spring with a total Hex de¢ciency. These
mice display a severe clinical phenotype consistent
with a combined gangliosidosis and mucopolysac-
charidosis [48]. These data indicate that glycosami-
noglycans like gangliosides are critical substrates for
Hex. It would also follow from these data that the
low residual level of Hex S in Sandho¡ disease is
su⁄cient to degrade MPS substrates in mice and
likely humans, as initially suggested by Kresse et
al. [26,49]. Because the hydrolysis rates for non-Ac-
tivator assisted substrates, e.g. MUG and the MPSs,
are V4000-fold greater than for GM2 [25], it is
likely the level of Hex activity necessary to prevent
substrate accumulation (the critical threshold) is
much lower for the MPSs than it is for GM2. Thus
the 1.5% residual Hex activity from Hex S in the
Sandho¡ mouse is su⁄cient to prevent MPS-accu-
mulation. Finally, normal bone marrow has been
transplanted into Sandho¡ mice. While the treated
mutant mice still died of gangliosidosis, their life ex-
pectancy was doubled and there was evidence of a
slower neurological progression of the disease [50].
This study supports the idea that bone marrow trans-
plants will not be an e¡ective therapy for lysosomal
storage diseases with severe neurological involvement
because of the di⁄culty in crossing the blood^brain
barrier by the secreted enzyme.
The AB-variant mouse produced a clinical pheno-
type intermediate to that of the other two. Storage of
GM2 was only slightly increased over the Tay^Sachs
mouse. However, in this case some GA2 storage was
also evident, but still at a level V10-fold less than
that of the Sandho¡ mouse [51]. The lower level of
GA2 storage suggests that this glycolipid can be hy-
drolyzed in the absence of the Activator, but that the
Activator is likely required for an optimal rate of
degradation.
Although earlier work had suggested the possibil-
ity that mouse Hex B could hydrolyze GM2 in the
presence of Activator [52], a more recent study with
the fully puri¢ed Hex isozymes from mice and re-
combinant mouse Activator, demonstrated that it
can not [53]. This study went on to show that in
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contrast to its human analog, the mouse Activator
can e¡ectively stimulate the hydrolysis of GA2 by
mouse Hex A and as well, but to much lesser extent
by mouse Hex B. Thus these mice models have dem-
onstrable species-speci¢c di¡erences in the Activator,
Hex A, Hex B, and a lysosomal sialidase, and indi-
cate that making extrapolations from them to the
human condition is risky.
5. Intracellular transport of the Hex isozymes and the
activator
Like other lysosomal and secretory proteins, both
the K- and L-chains of Hex and the Activator contain
cleavable signal peptides which cause their synthesis
to occur on polysomes attached to the rough ER
(Figs. 1 and 4). In the ER polypeptide chain folding,
Asn-linked glycosylation, disul¢de bond formation,
and dimerization also occur. Asn-linked glycosyla-
tion is the ¢rst step in targeting the pro enzymes to
the lysosome. The generation of a mannose-6-phos-
phate ‘tag’ on a high-mannose type oligosaccharide
occurs (Fig. 2) by the sequential action of two en-
zymes, i.e. UDP-GlcNAc:lysosomal enzyme N-ace-
tylglucosamine-1-phosphotransferase (in the cis Gol-
gi network and cis Golgi) and N-acetylglucosamine-
1-phosphodiester-K-N-acetylglucosaminidase, and re-
quires that the monomer obtain its near native fold-
ing pattern [54]. There are three sites on the K- and
four on the L-pro-polypeptides that receive Asn-
linked oligosaccharides in the ER, a ¢fth potential
site near the C-terminus of the L is not glycosylated.
Of these sites, the third on K, and the ¢rst and fourth
on L normally obtain the mannose-6-phosphate tag
in the cis Golgi [11,55]. In keeping with the hypoth-
esis that both subunits have very similar three dimen-
sional structures, the phosphorylated third glycosyla-
tion site in the K-chain aligns with the fourth in the
L-chain (there is no potential glycosylation site in K
that aligns with the ¢rst site in L) (Fig. 1). The phos-
phomannosyl residues serve as the essential compo-
nents for the high a⁄nity binding of lysosomal pro-
teins to one of two receptors, MPR-CI (mannose-6-
phosphate receptor, cation independent) and MPR-
CD (mannose-6-phosphate receptor, cation depend-
ent), in the trans Golgi network [56]. The protein^
receptor complex is then transported to a late endo-
some where the lower pH induces the dissociation of
the complex and the recycling of the receptor [57].
The generation of the mannose-6-phosphate tag is
not 100% e⁄cient, nor is the binding of properly
tagged molecules to a MPR. If either one of these
processes fail, the untagged and/or unbound pro-Hex
molecule follows the cell’s default pathway, i.e. it is
secreted (Fig. 2). In the lysosome, the single chain
pro-K- and -L-polypeptides (V68 kDa each) undergo
further proteolytic [13,58,59] as well as glycosidic [60]
processing to produce the complex polypeptide struc-
tures, held together by disul¢de bonds ‘[]’, of the
mature subunits (Fig. 1), i.e. [Kp (V14 kDa) Km
(V56 kDa)] [Lp (V17 kDa) Lb (V24 kDa)La
(V28 kDa)] (reviewed in [3,14]). The conversion of
the pro-polypeptides to the mature subunits is easily
detected by Western blot analysis [61] and can be
used as a marker for lysosomal incorporation [62].
The pro form of the Activator is also processed in
the lysosome at its N-terminus to produce a mature
chain of 162 residues. There is a single site for N-
linked glycosylation at Asn63. As well the Activator
has eight Cys residues forming four disul¢de bonds
which have recently been mapped to its primary se-
quence (Fig. 4) [63]. These bonds are likely respon-
sible for the activator’s great heat stability [34]. De-
pending on the composition of its oligosaccharide,
the pro-polypeptide can have an Mr as determined
by SDS-PAGE, of 22 kDa (high mannose type) or
24^27 kDa (complex type). As well, a small amount
Fig. 4. Primary structure of the Activator protein. The pro-
posed signal peptide is underlined, as is its single N-linked gly-
cosylation site. The sequence of the mature lysosomal polypep-
tide is shown between ‘[]’. The four disul¢de bonds present in
the monomeric protein are also shown. C138 is shown in bold.
This residue has been linked to Hex A binding and when mu-
tated to R results in the AB-variant form of GM2 gangliosido-
sis (Table 6).
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of non-glycosylated Activator (20 kDa) is also made
and transported out of the ER [64,65].
Two recent reports have studied the transport of
the Activator in human ¢broblasts [65] and human
epidermal keratinocytes [64]. In the former report,
the MPR pathway was identi¢ed as the likely major
biosynthetic route for the incorporation of the Acti-
vator into the lysosomes. However, it was also dem-
onstrated that a large percentage of the newly syn-
thesized Activator did not contain the mannose-6-
phosphate tag and was normally secreted. There is
also a MPR-independent mechanism for the re-cap-
ture of the Activator from the extracellular medium
[65,66] which is carbohydrate independent, but ap-
pears to require that the Activator be properly
folded. This is likely the primary endocytotic route
for the Activator; however, it is of a much lower
a⁄nity than re-capture through the MPR. In human
epidermal keratinocytes only 10% of the newly syn-
thesized Activator is phosphorylated, whereas 70% is
retained intracellularly. Thus in these cells there is
likely a major MPR-independent biosynthetic path-
way used by the Activator to get into the lysosome.
These data indicate that a large portion of newly
synthesized Activator molecules are secreted by nor-
mal cells and can then be re-captured (with or with-
out bound glycolipids) suggesting that the Activator
may have other in vivo functions likely related to its
alternate glycolipid transport function (Fig. 3).
6. Structure of the HEXA, HEXB and GM2A genes
The genes encoding the K- and L-subunits have
been isolated and characterized in detail. Both the
HEXA and HEXB genes are split into 14 exons span-
ning V35 and V40 kb [23,67,68]. HEXA transcribes
two mRNAs of 2.0 (major) and 2.3 (minor) kb both
of which encode the same prepro-K-polypeptide [24].
HEXB transcribes a single 2.2 kb mRNA [58,69].
Exons 2^14 of the two genes have splice junctions
at virtually identical positions in the coding se-
quence, i.e. within same aligned amino acid codon.
The striking conservation of intron positions between
the two genes provides a compelling argument that
they arose by duplication of an ancestral gene. At the
3P-end, two polyadenylation sites are located in exon
14 of the HEXA gene (responsible for the two
mRNA species), while there is a single site in exon
14 of the HEXB gene. Primers and the PCR condi-
tions needed to amplify the complete HEXA and
HEXB exons and their £anking intronic sequences
have been reported by Triggs-Raine et al. [70] and
Wakamatsu et al. [71], respectively.
Unlike other sphingolipid activator proteins
(SAP), i.e. SAP A^D, which are encoded by a single
gene on chromosome 10 and synthesized as a large
precursor polypeptide, prosaposin, the Activator is
encoded by GM2A on chromosome 5 (reviewed in
[33,35,37]). There is also a non-functional, processed
pseudogene related to the GM2A gene on chromo-
some 3 [72]. GM2A is a small gene of at least 16 kb
whose promoter has not been characterized. Three
exons were identi¢ed and a fourth extrapolated to
account for the remaining 81 bp of 5P-coding se-
quence not found in genomic clones. Among the
three introns, only intron 3 has been fully sequenced,
and the sequences of intron 1 and intron 2 and their
exonic junctions remain to be determined [73].
GM2A mRNA is about 2.5 kb, but contains only
582 nucleotides of actual coding region. The majority
of the remaining sequence consists of a long 3P-un-
translated end [73^75]. We have recently completed
the structure of the GM2A gene and developed
primers and PCR conditions which will allow others
to completely amplify the exons and their £anking
intronic sequences [239].
7. Mutations in the HEXA, HEXB and GM2A genes
associated with disease
7.1. Partial gene deletions
Three partial gene deletions have been described.
One in the HEXA gene removes 7.6 kb from the 5P-
end of the gene including exon 1 and is common in
the French-Canadian population (Table 4, row 1)
[76^78]. Two HEXB deletions also remove the 5P-
end of the gene. The ¢rst is 16 kb long [18], spanning
from 2 kb upstream of exon 1 to within the ¢rst 1.5
kb of intron 5 (Table 5, row 3) [79]. This mutation
makes up a surprising 26% of all Sandho¡ alleles
[79]. Some confusion exists in the literature because
a 50 kb HEXB deletion was also reported to be a
high frequency mutation causing Sandho¡ disease
BBADIS 61879 10-9-99
D.J. Mahuran / Biochimica et Biophysica Acta 1455 (1999) 105^138 123
(Table 5, row 2) [80]. The size of this deletion was
originally estimated by pulse ¢eld gel electrophoresis
[81]. This size estimate turned out to be incorrect,
and the 50 kb deletion was found to be identical to
the 16 kb deletion [82]. The second HEXB deletion is
indeed a 50 kb deletion, removing 25 kb 5P of the
promoter up to intron 6 (Table 5, row 1) [83].
Because of their high frequency, the HEXA and 16
kb HEXB gene deletions have been well character-
ized [77,79]. The deletion mechanism for both HEX
genes involved recombination between misaligned
small homologous non-coding DNA sequences be-
long to the Alu family of interspersed repeated
DNA. Patients homozygous for either of these
HEX gene deletions have been described and present
with the classical acute infantile form of GM2 gan-
gliosidosis; indicating that this clinical phenotype re-
sults from the total lack of all Hex A activity. This
conclusion also explains why the acute phenotype
shows the least clinical variations (see above).
7.2. Mutations a¡ecting mRNA splicing
The consensus sequences of the 5P- (Table 7) and
3P-splice sites (Table 8) are well established [84]. Of
these nucleotides four are invariant. These include
the ¢rst and last two nucleotides of each intron
(IVS, intervening sequence), i.e. +1g and +2t (Table
7) and 32a and 31g (Table 8) [85]. Of the 13 muta-
tions in the HEXA and HEXB genes that a¡ect RNA
splicing, seven involve one of these four nucleotides
(Tables 2^4). Patients homozygous for these muta-
tions or heterozygous with a second null mutation,
have no detectable mRNA and present with the
acute phenotype [3]. Outside of mutations at these
four nucleotides, the consensus sequences (Tables 7
and 8) have only a limited predictive usefulness. For
example, two other HEXA gene splicing mutations
are also associated with the acute phenotype, but
would not have been predicted to totally preclude
proper splicing based solely on the consensus sequen-
ces. The ¢rst is a 5-bp (tctcc) deletion, 38^312
IVS39 (Table 4, row 65), which interrupts some of
the string of 10 pyrimidine residues associated with
the 3P-splice site, but whose overall importance in the
splicing reaction has not been established (Table 8)
[70]. The second is a ‘g5a’ substitution in intron 4
(Table 4, row 18) [175]. A g5 is present in 84% of
the characterized wild-type splice junctions, but an
‘a5’ is found in another 9% (Table 7) [85].
The remainder of the splicing mutations allow
some normal mRNA to be produced, which results
in residual Hex A activity and a milder clinical phe-
notype. An interesting example of how the same sub-
stitution can have di¡erent outcomes depending on
its context within the splice junction can be seen by
comparing the Gÿ1A substitutions in the last nucleo-
tides of exons 5 and 7 of the HEXA gene (Table 4,
rows 32 and 49). An A31 is found in about 8% of
wild-type splice junctions, a G31 in 77% (Table 7)
[85]. In the case of the exon 5 mutation, no amino
acid substitution is encoded, but s 97% of the
mRNA produced is misspliced (producing low
steady-state levels of mRNA). The mutation in
Table 7
5P-Splice junction
Exon Intron
34 33 32 31 +1 +2 +3 +4 +5 +6 Consensus
Ca29/A34 C38/A35 A62 G77 g100 t100 a60 a74 g84t50
C A C A g t a a gCa t A-exon34/IVS34b
T C T GCA g t a a c c A-exon35/IVS35c
C C A GCA g t a a g a A-exon37/IVS37d
aPercentage of wild-type splice junctions containing this nucleotide at the indicated position.
bThe ‘g5a’ mutation in the HEXA gene at the exon34, IVS34 junction (A-exon34/IVS35) results in a 3% steady-state level of
mRNA (lacking exon 4) and infantile Tay^Sachs disease (Table 4, row 18).
cThe G31CA, i.e. G570CA, mutation results in no amino acid substitution, 3% of normal steady-state levels of mRNA (7% of this
lacking exon 5), subacute Tay^Sachs disease (Table 4, row 32).
dThe G31CA, i.e. G805CA, mutation results in a Gly269Ser substitution, V50% normally spliced mRNA, and the chronic form of
Tay^Sachs disease (Table 4, row 49), primarily due to the amino acid substitution.
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exon 7 resulted in a Gly269Ser substitution; however,
steady-state mRNA levels are lowered only by 50%,
the majority of which is properly spliced. While the
abnormal splicing due to the exon 5 mutation is re-
sponsible for the homozygous patient’s subacute phe-
notype [86], it is the amino acid substitution resulting
from the exon 7 mutation (resulting in an unstable K-
subunit [87]) that is the major cause of patients’
chronic Tay^Sachs phenotype [88]. The di¡erence
in the e¡ects of these seemingly identical substitu-
tions may result from the other components of
each exon/intron junction. The exon 7 junction is a
much closer match to the consensus than the exon 5
junction (Table 7). Therefore, exon 5 may have an
inherently less stable splice site and the additional
destabilizing e¡ect of the substitution is enough to
prevent the cell’s splicing mechanism from recogniz-
ing it.
Three HEXB gene mutations a¡ecting mRNA
splicing are of interest. In all three cases, some prop-
erly spliced mRNA is generated resulting in detect-
able levels of Hex A ranging from 10% for asympto-
matic individuals to 5% for two patients with
subacute Sandho¡ disease [89]. The distribution of
the major Hex isozymes in samples from individuals
with either of these mutations is very similar, all have
almost undetectable levels of Hex B. Thus the small
amounts of pro-L-chains being translated (with the
wild-type sequence) are preferentially formed into the
less stable Hex A heterodimers [89,90]. A mechanism
to explain this unexpected observation is presented
below.
The ¢rst of the above three HEXB mutations to be
described was a ‘g326a’ substitution at the 3P-end of
intron 12 (Table 5, row 16). This substitution result-
ing in an mRNA encoding an extra eight amino
acids between exons 12 and 13 (Table 8) [91]. Nor-
mal steady-state levels of L-mRNA are present with
s 95% encoding the additional eight amino acids.
The second mutation is associated with patients
whose biochemical phenotype was previously desig-
nated as ‘Hexosaminidase Paris’ because of their Hex
A/Hex B3 isozyme pattern [44]. Despite the fact
that these individuals are asymptomatic, i.e. their
clinical phenotype is dramatically di¡erent from the
individual with the ¢rst mutation, the correlations
between their genotype and biochemical phenotype
is nearly identical to that of the subacute patient’s.
Table 8
3P-Splice junction
Intron Exon
314 313 312 311 310 39 38 37 36 35 34 33 32 31 +1
ya78b y81 y83 y89 y85 y82 y81 y86 y91 y87 n c78 a100 g100 G55
cCac cCc tCa cCc tCt cCc cCc t c t c c a g G
td g t a a c g t t a a t a g C
te c c t t g g t a c t t a g A
gf a t t t a a a t t t t a g G
tg a a a c t g c t t g c g326Ca32 g G
aConsensus (y = c or t; n = any).
b% of occurrences in wild-type splice junctions.
cHEXA-IVS39: A vt-c-t-c-c deletion results in a low steady-state level of mRNA lacking exon 10 and acute Tay^Sachs (Table 4, row
65).
dP1 = The wild-type sequence of IVS310 and exon311 in the HEXB gene. A ‘C1252T’ mutation at position +8 in exon311 causes a
Pro417Leu substitution in the protein that has been shown to cause no adverse e¡ects; however, it also somehow results in a reduction
in normal mRNA splicing, and promotes the use of a cryptic splice site in the middle of exon 11, P2c, or the skipping of exon311 en-
tirely, P3f Both P2 and P3 contain premature Stop codons. This mutation results in variable clinical phenotypes, from very mildly af-
fected to subacute forms of Sandho¡ disease (Table 5, row 12).
eP2 = A cryptic splice site in the middle of exon311 of the HEXB gene (footnote d).
f P3 = The wild-type sequence for IVS312 in the HEXB gene (see footnote d).
gA ‘gÿ26a’ substitution in IVS312 produces this alternative splice site with a326 moving to the 32 position, i.e. g326 a32. The level of
mRNA is normal; however, s 95% is misspliced encoding the insertion of 8 amino acids. The 6 5% normally spliced mRNA is pre-
sumably responsible for the resulting subacute form of Sandho¡ disease (Table 5, row 16).
BBADIS 61879 10-9-99
D.J. Mahuran / Biochimica et Biophysica Acta 1455 (1999) 105^138 125
The only di¡erence is that cells from these individu-
als are able to produce residual Hex A levels about
2-fold higher than those of the subacute Sandho¡
patient’s (V10% of normal). These patients have
an 18-bp duplication consisting of 16 bp of intron
13 and the ¢rst 2 bp of exon 14 (Table 5, row 20).
This results in an in-frame insertion encoding an
elongated pro-L-chain (6 new amino acids) [89]. As
with the other mutation, normal steady state levels of
mRNA can be detected, with 90% of the mRNA
encoding the additional residues. However, both mu-
tations produce only small steady-state levels of elon-
gated mutant pro-L-chains, as detected immunologi-
cally (L-CRM). Additionally, the mutant pro-L-
chains are not phosphorylated and are recognized
by antiserum speci¢c for the unfolded form of the
L-protein. These data indicate that the elongated L-
polypeptides are not transported out of the ER [89].
Thus, the residual Hex activities in both cases arise
from the 5^10% of L-mRNA that is properly spliced,
i.e. normal L-subunits, not from the elongated mu-
tant L-protein.
The third HEXB mutation, C1252T in exon 11,
encodes a Pro417Leu substitution and is associated
with a wide range of clinical phenotypes and is the
common cause of chronic Sandho¡ disease (Table 5,
row 12). Since this nucleotide is 8 bp downstream
from the intron 10/exon 11 junction, it was surprising
to discover that its detrimental e¡ect on residual Hex
levels was not caused by the missense mutation, but
was caused by a large decrease in normally spliced L-
mRNA. The ¢rst description of the mutation was in
a homozygous, 39-year-old Japanese patient with
mental retardation and local panatropy [71]. The pa-
tient’s steady-state L-mRNA level was reduced to 8%
of normal. Three species of L-mRNA were charac-
terized. P1 (the longest species) was the normal tran-
script. P2 and P3 were alternatively spliced mRNA
(Table 8). The missplicing that generates either P2 or
P3 produces a frame shift and a premature Stop
codon. The ratio of these RNA species was
P1:P2:P3; 11:2:1 [71]. Thus P2 and P3, like other
mutant mRNA species that contain early Stop co-
dons, are unstable (discussed below) and only
V6% of normal mRNA is produced. This mutation
was next identi¢ed in a large French-Canadian fam-
ily. The subject was found to be heterozygous for the
C1252T in exon 11 and the 16-kb deletion mutation.
The presence of this null allele would suggest that the
patient should present with a more severe phenotype
than the homozygous Japanese patient. Surprisingly,
the patient was a 57-year-old man with normal in-
telligence, a 9-year history of severe watery diarrhea,
and di¡use abdominal pain. His family also con-
tained four other members (ages 51^61 years) who
were apparently of the same genotype, but had no
clinical phenotype. The same normal and misspliced
mRNA species, P1, P2 and P3, were found in cells
from this patient at about the same ratio [90]. Two
other Italian patients have also been identi¢ed with
the C1252T substitution. Both patients were hetero-
zygous, the ¢rst with the 16-kb deletion, and the
second with a mutation encoding a Cys292Tyr sub-
stitution (Table 5, rows 3 and 11). The clinical
phenotype of the ¢rst patient at age 34 years was
milder than the Japanese patient, but slightly more
severe than the French-Canadian, presenting with
normal intelligence and only an almost static lower
motor neuron disorder. On the other hand, at
34 years, the second patient had, in addition, severe
signs of cerebellar dysfunction, dysautonomia and
peripheral polyneuropathy [92]. The reason for the
di¡erent phenotypes associated with this mutation
is unclear. It may involve small genetic variations
between individuals in any one of the complex com-
ponents of the mRNA-splicing machinery, or it may
be related to variations in other genes directly asso-
ciated with ganglioside biosynthesis and metabolism.
Evidence from the study of 22 cystic ¢brosis patients
with splice-junction defects support the former con-
clusion. Even patients with the same CFTR muta-
tions produced drastically di¡erent levels of normal
transcripts in their respiratory epithelial cells [93].
The mechanism of how the above nucleotide sub-
stitution at an exon +8 position at a 3P-splice site can
have such profound e¡ects on mRNA splicing has
yet to be determined. It has been suggested that exon
sequences between +1 and +13 of 3P-junctions may
be involved in binding the protein U5200, a part of
the U5 small nuclear ribonucleoprotein particle
(snRNP), and may play a role in aligning the 5P-
and 3P-exons for ligation [94]. Clearly, there is
more to be learned about mRNA splicing mecha-
nisms.
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7.3. Mutations producing premature Stop codons
Naively, one would predict that premature Stop
codons would produce truncated proteins that may
have some residual activity depending on how close
to the normal C-terminus the new Stop occurs. This
is not true for mutations in HEX and many other
genes for two reasons. Firstly, early Stop codons
often result in unstable mRNAs, for reasons yet to
be determined. Secondly, proteins that are synthe-
sized in the ER undergo a form of quality control
by a resident ER system that recognizes abnormal
proteins (even those that could be partially function-
al), and retains and degrades them (discussed in Sec-
tion 7.4) [95].
Premature Stop codons can be generated directly
through a nonsense point mutation or indirectly
through a frame-shift. The latter can be generated
through abnormal mRNA splicing (above), dele-
tions, or insertions. There are numerous cases of
these types of mutation causing GM2 gangliosidosis
(Tables 4^6). In order to contrast the e¡ect on steady
state levels of mutant mRNA between inframe dele-
tion/insertion mutations and those that generate
frame shifts, ¢rst consider the example of the in-
frame insertion resulting in ‘Hexosaminidase Paris’
given above. As well, an example of an in-frame
deletion due to abnormal splicing is supplied by the
major mutation among Japanese patients with infan-
tile Tay^Sachs disease, a ‘g31t’ substitution in intron
5 of the HEXA gene (Table 4, row 35). This muta-
tion like the one producing Hexosaminidase Paris,
results in normal steady-state levels of mutant
mRNA [96]. However, in both cases, only low levels
of mutant pro-L- or pro-K-protein are detected (see
Section 7).
The major Ashkenazi Jewish mutation is an exam-
ple of a frame shift due to a small insertion produc-
ing a Stop at codon 431 (Table 4, row 74). Because
of its high frequency, the e¡ect of this mutation on
mRNA production has been well studied. In patient
cells there is no detectable steady-state mRNA; how-
ever, nuclear run o¡ experiments con¢rm that the
mutant HEXA gene is transcribed at a normal rate
[97]. There have been eight reported nonsense muta-
tions (Table 4, rows 6, 13, 30, 61, 67, 69 and 70;
Table 5, row 10) none of which have been shown
to result in detectable (Northern blot) levels of mu-
tant mRNA. Thus, premature Stop codons generally
lead to unstable mRNA.
One exception to the above generalization is a sin-
gle bp deletion mutation in exon 13 of the HEXA
gene (Table 4, row 84). This mutation results in nor-
mal steady-state levels of K-mRNA encoding a loss
of 22 residues from the C-terminus of the pro-K-
chain. However, only low levels of the mutant pro-
K-chain can be detected [98]. These data suggest that
the closer the Stop codon is to the 3P-end of the
coding region the more stable may be the mutant
mRNA. The correlation between the location of
the premature Stop codon and the steady-state level
of L-mRNA (normally codon 557) was probed in
cells from three patients with acute Sandho¡ disease
[99]. Patients 1 and 2 were heterozygous for the com-
mon 16 kb deletion and either a substitution produc-
ing a Stop at codon 284 (Table 5, row 10), or a
deletion producing a Stop at codon 451 (Table 5,
row 14). The third patient was heterozygous for
two deletion mutations producing Stops at codons
274 and 454 (Table 5, rows 9 and 13). The steady-
state levels of L-mRNA in patient cells were quanti-
tated for Stop codons at: 284, 0.8% (of normal L-
mRNA); 451, 30%; and the combined 274 and 454,
1.8% [99]. Thus, because of the large disparity be-
tween the e¡ects of premature Stop codons at 451
(30%) and 454 (6 1.8%), there is only partial support
for the idea that the further the Stop codon is 5P the
more severe its e¡ect on mRNA stability. Clearly
more work is needed to elucidate the mechanism
by which premature Stop codons produce unstable
mRNA.
7.4. Missense mutations
To date, missense mutations at all but two codons
in either HEX gene result in normal levels of mutant
mRNA and a dramatic reduction in both mature L-
and/or K-protein (CRM) with a proportional reduc-
tion in Hex B and/or Hex A activity in patient cells.
As well, in Tay^Sachs disease Hex B activity and L-
CRM are elevated, whereas in Sandho¡ disease levels
of Hex S and K-CRM are barely detectable, despite
normal K-mRNA levels [7,18,24,62]. These observa-
tions plus pulse-chase studies [62,100^102] suggest
that mutant forms of either subunit, as well as the
majority of wild-type K-chain in cells de¢cient in L,
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undergo rapid degradation at an earlier stage in their
biosynthesis and intracellular transport, i.e. the ER/
cis Golgi network (reviewed in [36,103]) (Fig. 2).
Unlike the majority of cellular proteins which are
synthesized in the cytosol, lysosomal, secretory, and
plasma membrane proteins are synthesized in the
oxidizing environment of the ER. For these proteins
it is now well accepted that unless each folds into its
near native conformation and in some cases forms a
functional multimer with another subunit(s), it is un-
able to pass out of the ER/cis Golgi network and
into the cis Golgi, where further Golgi transport
and either secretion or plasma membrane insertion
continues via bulk £ow [104]. Thus, the di¡erence in
the secretion rates of various proteins is directly re-
lated to their rate of folding and if necessary oligom-
erization (reviewed in [105^107]).
The retention through recycling between the ER
and the cis Golgi network of unassembled subunit(s)
of multimeric proteins, even though properly folded
[108], is achieved through interactions with resident
proteins which are themselves normally recycled be-
tween these compartments [109,110], i.e. chaperones,
such as GRP94; protein disul¢de isomerase, PDI;
BiP; Erp72; ER60; Calreticulin; and Calnexin (re-
viewed in [111]). These proteins are also believed to
assist normal monomers in their folding, while re-
taining those that are deemed to be ‘misfolded’,
e.g. because of mutation, and accelerate their degra-
dation (Fig. 2) [112,113].
Other types of chaperones include ‘catalysts that
regulate folding’, e.g. sugar processing enzymes, and
‘transport subunits and molecular escorts’, e.g. pro-
peptides and speci¢c subunits of oligomers [111]. In
the case of the L-subunit of Hex it has been shown
that at least partial Asn-linked glycosylation is re-
quired for e⁄cient ER to Golgi transport [11]. As
well, although the precursor forms of both Hex A
and B have the same substrate speci¢city and kinetic
properties as the mature forms (Hou et al. unpub-
lished results), the N-terminal pro-L-peptide (Fig. 1)
is required for the proper folding of the pro-L-poly-
peptide in the ER and transport to the Golgi [114].
Disease causing, missense transport mutations lo-
cated in the Kp or Lp sections of the subunits have
also been described (Table 4, rows 5 and 6; Table 5,
row 5).
It appears that for Hex dimer formation is neces-
sary for ER to Golgi transport and that unlike L-
homodimers (Hex B), homodimers of the K-subunits
(Hex S) are not readily formed. Thus, the L-subunit
can be viewed as a ‘transport subunit’ [111] necessary
for transport of the K in pro-Hex A out of the ER.
Such a di¡erence in subunit a⁄nity would also allow
the cell to speci¢cally retain K-subunits and increase
their concentration in the ER/cis Golgi network,
which in turn would promote the formation of het-
erodimeric Hex A by newly synthesized L-subunits
(Fig. 2), rather than the more stable Hex B homo-
dimers (reviewed in [36]).
The above transport mechanisms explain the lack
of detectable Hex B, but not Hex A in cases where
splicing mutations lower the levels of L-mRNA en-
coding normal pro-L-polypeptides, e.g. ‘Hexosamini-
dase Paris’ (Table 5, row 20). They also explain why
only low levels of CRM containing missense muta-
tions, or small in-frame insertion or deletion muta-
tions are found in patient samples. These mutations
must either alter the monomers’ ability to initially
fold or decrease the stability of its folded form which
in turn reduces the concentration of folded mono-
mers and inhibits dimer formation [87]. Alterna-
tively, at the very least, the mutations must change
some surface properties of the a¡ected monomer suf-
¢ciently so that it is recognized as being ‘abnormal’
by one or more chaperones, resulting in its retention
and degradation. Although it would seem apparent
that degradation of these proteins would occur in the
ER, two recent reports strongly suggest that at least
in some cases, e.g. CFTR [115], degradation occurs
in the cytosol through the ubiquitin^proteasome
pathway [116]. If this hypothesis is correct, some
unidenti¢ed retrograde transport pathway between
the lumen of the ER and the cytosol must exist.
The presence of the above ‘quality control system’
in the ER suggests that subunits with missense mu-
tations, even those associated with the most severe
clinical phenotype, may not of necessity be incapable
of forming a partially functional Hex A, but may be
prevented from doing so by their increased a⁄nity
for one or more chaperones. In keeping with this
hypothesis, when three KcDNAs encoding di¡erent
disease causing HEXA missense mutations (Table
4: row 46, Gly250Asp, subacute; row 49, Gly269Ser,
chronic; row 79, Glu482Lys, acute) were individually
over-expressed in COS-1 cells along with the wild-
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type LcDNA, surprisingly high levels of Hex A ac-
tivity were detected as compared to activity levels in
patient cells [87]. Similar observations were made by
other groups studying HEXA missense mutations as-
sociated with the chronic and pseudo-de¢ciency phe-
notypes (Table 4, rows 29, 43, 44, 46 and 49)
[117,118], and by a group studying a Leu176Phe sub-
stitution in another lysosomal enzyme, L-glucuroni-
dase, associated with mucopolysaccharidosis (MPS
VII) [119]. The e¡ect of over expression would be
to greatly increase the concentration of Hex (or L-
glucuronidase) pro-polypeptides (mutant or wild-
type) in the ER and either help drive protein fold-
ing/dimer formation through a form of mass action
[120^122], and/or more simply by saturating the
chaperone(s) that recognize the mutant protein as
‘abnormal’. Thus, the major detrimental e¡ect
caused by many HEX missense mutations is at the
level of intracellular transport rather than structure^
function.
Because of the ER quality-control system the ini-
tial hope that we would learn a great deal about
structure^function relationships within the two Hex
subunits by characterizing missense mutations asso-
ciated with GM2 gangliosidosis has not been fully
realized. Early pulse-chase metabolic labeling experi-
ments were only able to group these mutations into
two classes. Those that were able to obtain their
lysosomal targeting label (mannose-6-phosphate)
and remain soluble, i.e. could be extracted from pa-
tient cells without detergent, and those that did nei-
ther. To obtain their targeting label, lysosomal pro-
teins must be at least partially folded [54] and be able
to enter the cis Golgi network [123]. It would follow
that those mutant proteins that retain some ability to
fold would also likely be associated with the less
severe clinical phenotypes. Expression of such muta-
tions in COS or even CHO cells (over expression is
less pronounced in CHO cells) often produce reason-
able levels of Hex which are characteristically also
heat labile. Examples of such mutations are
KGly269Ser [87] KTyr180His [117], LPro504Ser [29],
LArg505Gln [124], and LAla543Thr [125], all of which
are associated with the chronic forms of GM2 gan-
gliosidosis.
7.4.1. Mutations that produce a ‘pseudo-de¢ciency’ of
Hex A
Mutations at two codons in the HEXA gene are
responsible for most of the false-positive results ob-
tained by enzyme-based Tay^Sachs screening proce-
dures where carrier status is de¢ned as 6 48% Hex A
(of total serum Hex) [126,127]. It is fortunate from a
historical perspective that these types of mutation are
present at a very low frequency in the Jewish com-
munity. Otherwise they would have caused many un-
explainable false-positive results in carrier-screening
and more seriously in prenatal diagnoses. Further-
more, they would have led to even more confusion
in the 1970^1980s over the genetic cause(s) of Tay^
Sachs disease.
Two missense mutations resulting in an
KArg247Trp or an Arg249Trp substitution in exon 7
produce a ‘pseudo-de¢ciency’ of Hex A (Table 4,
rows 43 and 44). They have been reported to produce
0^15% of normal Hex A in serum, 13^24% in leuko-
cytes and 8^26% in ¢broblasts [118,128^130]. These
mutations were initially reported to a¡ect the K-sub-
unit’s ability to hydrolyze MUG and MUGS to a
greater extent than its ability to hydrolyze the Acti-
vator:GM2 ganglioside complex (reviewed in [3]).
However, Hex recognizes only the terminal L-linked
GalNAc or GlcNAc residue of a substrate, making
the nature of the aglycone moiety of little impor-
tance. Therefore, the arti¢cial MUG and MUGS
substrates represent the minimal structures needed
for enzyme-recognition and K-speci¢city, respec-
tively, and while it has been shown to be possible
for a mutation to a¡ect the rate of Activator:gan-
glioside hydrolysis (a much more complex event in-
volving protein^protein interactions) and not MUGS
hydrolysis, e.g. LPro504Ser (discussed below [29]), the
reverse would be unlikely. Recently Cao et al. have
shown that the lower activities associated with these
mutations are, like other missense mutations propor-
tional to the levels of mutant intracellular, mature
Hex A protein, i.e. as determined by mature K-
CRM, present [118]. This report goes on to identify
instability of the mutant K-chain (as Hex A) either in
the lysosome or in extracellular £uids as the cause of
the apparent de¢ciency in patient samples. This is a
novel biochemical phenotype, as all other character-
ized missense mutations that result in lower CRM,
do so because of defects in ER-transport. Thus, it
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can be concluded that the low level of steady-state
lysosomal Hex A that is present, is fully functional
and above the ‘critical threshold’, s 5% [45], neces-
sary to prevent ganglioside storage.
Recent molecular modeling of human Hex using
the crystal structure of bacterial chitobiase [131] sug-
gests that the residues involved in the pseudo-de¢-
ciencies may be located on the surface of the folded
protein. As well, from a biochemical perspective,
their change from charged hydrophilic to aromatic
hydrophobic residues is highly non-conservative
and would be expected to disrupt protein folding
unless such residues were located on the surface of
the protein [121]. The appearance of a hydrophobic
residue on the protein’s surface may serve as a rec-
ognition site for proteolytic cleavage in the endo-
some/lysosome, or alternatively as one of the signals
for chaperone binding in the ER [132^135].
7.4.2. The B1 variants of Tay^Sachs disease
The missense mutations at two codons have pro-
duced some clues to the active site of Hex. They are
associated with an unique biochemical phenotype
called the B1-variant of Tay^Sachs disease (Table
4, rows 26, 27, 28 and 48). A mutation at a third
residue was also linked with this phenotype,
KVal192Leu (Table 4, row 36); however, it has re-
cently been shown that this is a typical transport
mutation [136].
Patients with the B1 variant were originally
thought to have an activator defect (the AB-variant
form of GM2 gangliosidosis), because they express
both Hex A and B activities as assayed with neutral
(common) substrates, e.g. 4-MUG. However, unlike
the normal Hex A found in the true AB-variants,
Kytzia et al. found that B1 variant Hex A was in-
active toward an K-speci¢c, GlcNAc-6-sulfate con-
taining substrate (as well as GM2 ganglioside even
in the presence of added activator protein), and they
suggested the presence of a mutation at or near the
active site of the K-subunit [137].
A hypothesis similar to that made by Kytzia et al.
was advanced by Suzuki and colleagues [138,139]
who identi¢ed the ¢rst speci¢c mutation linked to
the B1 phenotype in ¢ve of six patients examined,
a G533A substitution encoding a change in KArg178
to His (Table 4, row 27). Patients homozygous for
this mutation present with a subacute phenotype,
whereas those that are heterozygous present with
an acute associated second allele present with a no-
ticeably more severe phenotype [140]. Suzuki and
colleagues originally noted that Arg178 is found in a
stretch of eight identical amino acids in the aligned
primary structures of the K- and L-subunits and that
the His substitution was predicted (by computer
analysis) to cause a change in the secondary structure
of the K-polypeptide.
Two other mutations at the same B1-codon have
been described (Table 4, rows 26 and 28),
KArg178Cys [141] and KArg178Leu [70]. In these two
cases, the patients presented with the more severe
acute phenotype. This increased severity is consistent
with biochemical data from the patients’ samples
which suggest that lower levels of mutant K-chain
were able to form heterodimers (Hex A) and exit
the ER (detected as mature K-CRM). In turn, these
data correlate with the degree to which the amino
acid substitutions are conservative, i.e. for ArgsHis
ECysvLeu [142].
The knowledge of the exact K-mutation, even
when coupled with the biochemical characterization
of the Hex A from B1 patients, did not fully de¢ne
the biochemical impact of the Arg178His substitution
on the K-subunit, because of the presence of a nor-
mal, active L-subunit. It was not known whether the
a¡ected K-subunit had undergone a partial change in
substrate speci¢city, i.e. become L-like and could no
longer e⁄ciently bind negatively charged substrates,
but could still hydrolyze neutral substrates, or if it
had entirely lost its catalytic ability. Expression of a
mutant K-cDNA alone to produce a mutant form of
Hex S for analyses could also be problematic due to
this isozyme’s over-sensitivity to any K-amino acid
substitution, e.g. as demonstrated by its failure to
form KGly269Ser Hex S (associated with the mild
chronic form of Tay^Sachs disease) [87,143]. To
overcome these problems, we took advantage of the
common evolutionary origins of the two subunits
and analyzed the biochemical consequences of the
B1-substitution in the K-subunit by in vitro muta-
genesis of the aligned codon in the L-subunit,
LArg211His, to produce a stable mutant homodimer.
We found that the substitution did not a¡ect dimer
formation or cellular transport, but caused a near
total loss of activity towards MUG. Consistent
with the initial computer-predictions of its e¡ects
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on secondary structure (reviewed in [144]), we noted
small additional changes in the lysosomal stability
(corrected by growing cells in leupeptin) and the
rate of processing of the pro-L-subunit [61].
Although there was no re-activation of the mutant
Hex B protein, these additional e¡ects were totally
eliminated when a more conservative substitution,
LArg211Lys, was made. Through kinetic studies and
the use of Arg-speci¢c modifying agents, we were
able to conclude that KArg178 and LArg211 are active
site residues, likely part of the catalytic sites (normal
Km, but only 0.2% of normal Vmax for MUG), in
Hex [145]. However, the recent molecular modeling
from bacterial chitobiase suggests that these active
Arg residues are directly involved in substrate bind-
ing, interacting with OH3 and OH4 of a L-GlcNAc
substrate, docking the substrate in its proper orien-
tation in the active site [131]. These data are not
inconsistent with ours if the very low level of immu-
no-precipitated Hex activity we were detecting was
from the endogenous COS cell background, and we
were not able to increase the MUG concentration
su⁄ciently (because of its low solubility) to activate
a mutant human Hex B with a highly increased Km.
We have recently developed a method for removing
99.99% of endogenous Hex from transfected cell me-
dia using an epitope-tag that does not interfere with
ER-transport (Hou et al. unpublished data). A re-
examination of Arg211Lys-Hex B demonstrated that
it had a Vmax of 0.2% of normal and a Km increased
more than 10-fold. The very low apparent Vmax in-
dicates the critical role this residue must play in cat-
alysis. These data suggest that the Arg does bind the
substrate, but likely binds much better to the transi-
tion state intermediate, thus assisting catalysis. Thus
even if higher MUG concentrations were achievable
in our initial studies, we would not have seen the
increase in residual activity expected from a mutation
that only e¡ects Km. More support for the bacterial
model comes from the comparative molecular mod-
eling of Streptomyces plicatus (Sp-Hex) [146]. The
overall three-dimensional structure that was gener-
ated for Sp-Hex (also using the Serratia marcescens
chitobiase X-ray structure [131,147]) was similar to
the previously published model for human Hex [131].
For Sp-Hex, Arg162 aligns with KArg178. When
Arg162was converted to His and the enzyme puri¢ed
from transformed Escherchia coli, it was found to
have a Km increased by 40-fold and a Vmax of 20%
of wild-type Sp-Hex (for MUG Km = 0.14 mM,
Vmax = 3.2 mmol h31 mg31) [146].
We analyzed the second mutation associated with
the B1 variant (Table 4, row 48), KAsp258His [148], in
the same manner as above. The two patients origi-
nally described were heterozygous for this mutation
and KArg170Trp (associated with the acute pheno-
type, Table 4, row 24). They were found to have
Hex A levels by MUG that were below that of
Tay^Sachs carriers, but above that of patients. On
the other hand, MUGS activities were at the level
typical for an a¡ected individual [149]. When we ex-
pressed a conservative substitution at the analogous
L-residue, LAsp290Asn, we found that the mutant
Hex B had a Km for MUG 2.5-fold higher than the
wild-type enzyme, and that the reduced apparent
Vmax we observed was primarily caused by a reduc-
tion in mature L-CRM, i.e. kcat was estimated to be
70% of wild-type [150]. Thus, this mutation, and by
extension the KAsp258His appears to a¡ect both sub-
strate binding and intracellular transport. Data from
the molecular modeling of human Hex based on bac-
terial chitobiase suggest that the KAsp258 is only in-
directly involved in substrate binding (chitobiase
Asp448 forms a hydrogen bond with its substrate
through a water molecule). Thus it plays a much
less crucial role than KArg178 and is not critically
involved in stabilizing any transition state intermedi-
ate [131]. This conclusion is also supported by the
molecular model generated for Sp-Hex (see above)
[146]. In Sp-Hex Asp246 aligns with KAsp258. When
Asp246 was converted to Asn and the enzyme puri¢ed
from transformed E. coli, its Km was increased by
1.2-fold and its Vmax was decreased by 2-fold [146].
The method of expressing an K-mutation in the
aligned residue in the L-chain is useful in di¡erenti-
ating between mutations that a¡ect the active site
and those that reduce intracellular transport. Active
site mutations remain inactive, as described above,
while transport or folding mutations give increased
residual activities. Two such K-folding mutations
(Table 4, rows 29 and 49) have been analyzed by
this method [87], KTyr180His, expressed as
LTyr213His [117], and KGly269Ser, expressed as
LGly301Ser. Both of these are associated with the
chronic form of Tay^Sachs disease and result in an
K-chain that is unstable at 37‡C, indirectly a¡ecting
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its ability to associate with the L. When either muta-
tion was expressed as its L-analog, nearly normal
levels of Hex B activity and protein were found as
compared to COS cells transfected with the wild-type
L-cDNA. However, in keeping with the conservation
of structure^function relationships between the two
subunits coupled with inherently greater heat stabil-
ity of the LL-dimer, while both mutant Hex B en-
zymes were stable at 37‡C, they had a decreased
heat stability at 50‡C.
7.4.3. The LPro504Ser substitution
We found that two French-Canadian patients (sis-
ters) with chronic Sandho¡ disease were heterozyg-
ous for the common v16 kb HEXB allele [79,90]
and a C1510T transition encoding a Pro504Ser substi-
tution (Table 5, row 17) [29]. Since the former allele
produces no L-mRNA, the latter is responsible for
the 15^25% [90,151] residual Hex A activity (using
MUG) we initially reported to be present in the pa-
tients’ ¢broblasts, and their chronic phenotype.
Western blotting had also indicated a similar reduc-
tion in the amount of mature L-protein [90]. This
level of Hex A activity is similar to that found in
¢broblasts from pseudo-de¢ciency patients (8^26%,
see above) and well above what is believed to be
the critical threshold necessary to prevent GM2 stor-
age. Thus it was di⁄cult to understand why these
two patients present with chronic GM2 gangliosido-
sis. Two possibilities were considered. First, that the
L-mutation is somehow a¡ecting the K-active site,
lowering its activity towards MUGS and GM2, e.g.
a new type of B1-variant. Second, the mutant L-sub-
unit is a¡ecting the ability of Hex A to bind the
Activator:GM2 complex. Using mutant and normal
Hex A produced in co-transfected CHO cells, it was
demonstrated that, like other HEX mutations asso-
ciated with chronic phenotypes (see above) the mu-
tant KLPro504Ser Hex A had decreased heat stability
coupled with an increased retention in the ER. How-
ever, the Km values of the mutant Hex A for both the
MUG and MUGS substrates were normal. Finally
we assessed the ability of the mutant Hex A to hy-
drolyze its natural substrate, the Activator:GM2
complex. These data demonstrate that the LPro504Ser
mutation reduces the ability of the mutant Hex A to
hydrolyze GM2 in the presence of human Activator
by 3-fold. When this reduction in the speci¢c activity
of the mutant towards GM2, but not MUG or
MUGS, is factored into our residual Hex A activity
measurement, the patients’ activity levels are reduced
to 3^9% of normal. This is very close to the critical
threshold values discussed above and is consistent
with the chronic phenotype observed in the patients.
Recently we [152] and others [153] have reported
the characterization of K-L-fusion proteins. Although
some of our conclusions di¡ered, both studies con-
cluded that the C-terminus of the L-polypeptide is
important for the correct binding of the Activa-
tor:GM2 complex. The characterization of this nov-
el, naturally occurring mutation strengthens these
conclusions and identi¢es the region surrounding
Pro504 as the area in the C-terminus most likely to
be responsible for this function.
7.4.4. The Cys138Arg substitution in the Activator
There have been only four mutations described
that are associated with the rare AB-variant form
of GM2 gangliosidosis (Table 6, row 3). Of these
the Cys138Arg was the ¢rst to be described
[154,155] and is the most interesting from a struc-
ture^function point of view [34]. Like other missense
mutations in the Hex A subunits, the Cys138Arg sub-
stitution results in the mutant protein being retained
and degraded in the endoplasmic reticulum of the
patient’s ¢broblasts [155]. In order to characterize
the biochemical e¡ects of this substitution, we ex-
pressed the mutant protein in transformed bacte-
ria1. The mutant protein retained 1^2% of the wild-
type’s speci¢c Hex A co-factor activity. The presence
of even this small amount of activity in the mutant
protein coupled with a nearly normal CD spectrum,
strongly suggest that no major tertiary or secondary
structural changes, respectively, had occurred due to
the mutation. However, we found that the mutant
protein had a 14-fold reduction in its heat stability
at 60‡C, suggesting some localized change in tertiary
structure. The loss of a disul¢de loop was chemically
con¢rmed, which probably is responsible for this de-
crease. A kinetic analysis detected a large increase in
the apparent Km of Hex A for the mutant Activator;
1 Bacterial expression requires refolding of the Activator from
inclusion bodies [32,66,156]. Similar refolding methods do not
work for the Hex B (unpublished data).
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however, there was no apparent change in Vmax. A
£uorescence dequenching assay was used to evaluate
the ability of the mutant protein to transport lipids
and bind GM2 [156]. These assays detected no di¡er-
ence between the wild-type and mutant proteins, in-
dicating that the Cys138Arg substitution has no e¡ect
on these functions. We conclude that the mutation
speci¢cally a¡ects a domain in the Activator protein
that is responsible for the recognition of the Activa-
tor:GM2 complex by Hex A. Recently the four di-
sul¢de bonds of the Activator have been mapped by
Schu«tte et al. (Fig. 4) [63]. Their study adds support
to our hypothesis and localized the domain to the
central portion of the Activator. They note that the
bond between the ¢rst and last Cys (39^183) is a
feature that is shared with other sphingolipid activa-
tor proteins (needed for lipid binding?), SAP B and
C, which are formed post-translationally from pro-
saposin (reviewed in [37]). The other three disul¢des
occur within the middle third of the Activator mono-
mer in a stretch of 39 residues, 125^136, 99^106 and
112^138, with the latter forming a ‘clamp’ around
the former (Fig. 4). It was further noted that seven
of the protein’s 17 Pro groups also reside in this
region. These data suggest that the central part of
the Activator is kept in a restricted conformation,
likely needed for stability and to ful¢l some speci¢c
function, e.g. interacting with Hex A [34].
8. Summary
The elucidation of naturally occurring mutations
associated with each of the three GM2 gangliosidoses
in either the HEXA (encoding the K-subunit of Hex
A, Tay^Sachs), HEXB (encoding the L-subunit of
Hex A, Sandho¡), or GM2A (encoding the GM2
activator protein, AB-variant form) genes has made
some genotype^phenotype (biochemical and clinical)
correlations possible (Tables 4^6). The characteriza-
tion of the e¡ects of a few of these mutations on the
translated protein have led to a better understanding
of normal cell biology and given clues to the location
of functional residues and/or domains in Hex A and
the Activator. The e¡ects of many others on the
protein are linked with the ‘quality control’ system
in the ER and have focused attention on the need to
understand the mechanisms involved in the identi¢-
cation, retention and degradation of ‘abnormal’ and/
or unassembled proteins in this organelle. More gen-
eral questions have been posed by the biological con-
sequences of other HEXA and HEXB mutations af-
fecting mRNA processing, transport and/or stability.
The history of the study of Tay^Sachs disease is an
excellent example of how the interest in a human
disease can stimulate research that has resulted in
advances in a number of more general biological
and biochemical ¢elds.
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